Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 2.1% - Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares rose 2.1% during trading on Friday . The company traded as high as $6.54 and last traded at $6.37. Approximately 5,629,128 shares changed hands during trading, a decline of 78% from the average daily volume of 25,496,789 shares. The stock had previously closed at $6.24.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Leerink Partners lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $8.25.

Recursion Pharmaceuticals Trading Down 7.0 %

The business has a fifty day moving average of $7.62 and a 200-day moving average of $7.06. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -4.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals's revenue was down 57.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.42) earnings per share. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. boosted its position in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock valued at $12,789,000 after purchasing an additional 288,926 shares during the period. Accel Wealth Management acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $310,000. FMR LLC boosted its position in shares of Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after purchasing an additional 170,810 shares during the period. Avanza Fonder AB acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $580,000. Finally, State Street Corp boosted its position in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company's stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.